anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a medicament for treating child antiadoncus. The formula adopts Indian trum etflower seed, grosvener siraitia, fig, Chinese globeflower flower, dwarf lilyturf tuber, liquoric root, chrysanthemum, honeysuckle flower, boat-fruited scaphium seed, pilose Asiabell root, peppermint, root of straight ladybell, balloon flower, Chinese white olive, indigowoad root, wild chrysanthemum, mulberry leaf and medicine terminalia fruit. A preparation method is as follows: cleaning and air-drying the traditional Chinese medicines, and the medicament can be mixed with an appropriate amount of tea for drinking in the tea-brewing way, and can also be decocted for administration. The medicament has the effects of clearing heat and toxin, resisting bacteria, diminishing inflammation, realizing detumescence, reliving pain, eliminating phlegm, evacuating pus, relieving sore throat, restoring voice, invigorating spleen, replenishing qi, nourishing blood, promoting fluid production, resisting virus and the like. Simultaneously, the medicament can treat child chronic pharyngitis, the efficacy is significant, and the medicament can further prevent rheum, influenza, epidemic meningitis and other diseases. The treatment rate for the child antiadoncus can achieve 98%, the cure rate can achieve 95%, and the recurrence after healing can be avoided.
The invention relates to posture and breathing improvement devices, systems and methods. A system for improving posture and deep breathing may include: a sensor device; a posture/respiration improvement software program comprising one, two or a combination of a posture improvement system interface and a respiration improvement system interface; and one or more user devices. The sensor device may be physically associated with the user and may be in communication with the posture improvement software program. The sensor device may include: one or more sensors for monitoring the position and movement of the user. The system may calculate one or more optimal posture positions and breathing exercises for the user based on the data transmitted by the sensor device and the collected information about the user. The system may monitor the user's consistency with the optimal pose location and may display the consistency on the pose improvement system interface. The system may detect and notify the user of one or more inconsistencies, thereby alerting the user to maintain at least one optimal postural position and periodically take deep breaths.
Candida albicans is the main fungal species involved in oral candidiasis, and its increasing resistance to pharmacological treatment encourages the search for improved antifungal agents. Lavandula dentata L. essential oil (LD-EO) has been recognized for its antimicrobial activity, but little is known about its role against oral C. albicans. This study evaluated the antifungal and antibiofilm activities, mechanisms of action, and toxicity of LD-EO from Brazil against oral strains of C. albicans. Antifungal activity was assessed based on Minimum Inhibitory Concentration (MIC), Minimum Fungicidal Concentration (MFC), association study with miconazole (Checkerboard method), and sorbitol and ergosterol assays. Inhibition of biofilm formation and disruption of preformed biofilm were considered when studying the effects of the product. Additionally, the toxicity of LD-EO was evaluated by a hemolysis assay on human erythrocytes. Phytochemical analysis by gas chromatography-mass spectrometry identified eucalyptol (33.1%), camphor (18.3%), and fenchone (15.6%) as major constituents. The test substance showed mainly fungicidal activity (MIC100 = 8 μg/mL; MFC = 16 μg/mL), including against two miconazole-resistant isolates of C. albicans. The effects of LD-EO were synergistic with those of miconazole and appeared not to involve damage to the fungal cell wall or plasma membrane. Its effectiveness in inhibiting biofilm formation was higher than the effect of disrupting preformed biofilm. Finally, the product exhibited low hemolytic activity at MIC. Based on the favorable and novel results described here, LD-EO could constitute a promising therapeutic alternative for oral candidiasis, including miconazole-resistant cases.
It is very important for midwives to implement and teach the interventions that will enable pregnant women to take an active role in this period, in terms of perception of the role of motherhood and pregnancy distress. . The literature provides a data source for leopard maneuvers. However, I and II. There is no study on the effect of Leopold maneuvers on pregnancy distress and the perception of maternal role. This study, which is planned to support and develop awareness in this area, is important in terms of literature.
The utilization of atypical antipsychotics (AAPs) often leads to metabolic syndrome (MetS) in schizophrenia (SZ) patients. Macrophage migration inhibitory factor (MIF) is an important MetS-related cytokine. To investigate the potential association between the MIF-794 CATT5-8 polymorphism and AAP-induced MetS in SZ patients, data from 375 chronic SZ patients who received AAP treatment for a minimum of one year were included. MIF-794 CATT polymorphism genotyping and plasma MIF quantification was performed. The metabolism status of all patients was assessed according to the NCEP-ATP III criteria. Individuals who displayed at least three of the five risk factors (waist circumference, high-density lipoprotein cholesterol, triglycerides, fasting glucose levels, and blood pressure) were diagnosed with MetS. The prevalence of MetS in SZ patients with MIF CATT >5/6 was significantly higher than in those with CATT 5/5-5/6. In female patients, MIF CATT >5/6 was associated with an elevated risk of AAP-induced MetS after adjusting for covariates, particularly regarding abdominal obesity, and the mediating effect of plasma MIF levels was significant. In conclusion, MIF CATT >5/6 increased the risk of AAP-induced MetS among females with chronic SZ. The MIF-794 CATT5-8 microsatellite polymorphism may be a unique indicator for AAP-induced metabolic adverse effects in female SZ patients.
INTRODUCTION: Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study sought compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI).
METHODS: The COMBINE trial compared anti-TNF monotherapy with combination therapy with methotrexate in patients with PCD. In this secondary analysis, a comparison of time-to-treatment failure among patients with normal BMI vs BMI Z -score >1, adjusting for prescribed anti-TNF (infliximab [IFX] or adalimumab [ADA]), trial treatment assignment (combination vs monotherapy), and relevant covariates. Median anti-TNF levels across BMI category was also examined.
RESULTS: Of 224 participants (162 IFX initiators and 62 ADA initiators), 111 (81%) had a normal BMI and 43 (19%) had a high BMI. High BMI was associated with treatment failure among ADA initiators (7/10 [70%] vs 12/52 [23%], hazard ratio 0.29, P = 0.007) but not IFX initiators. In addition, ADA-treated patients with a high BMI had lower ADA levels compared with those with normal BMI (median 5.8 vs 12.8 μg/mL, P = 0.02). IFX trough levels did not differ between BMI groups.
DISCUSSION: Overweight and obese patients with PCD are more likely to experience ADA treatment failure than those with normal BMI. Higher BMI was associated with lower drug trough levels. Standard ADA dosing may be insufficient for overweight children with PCD. Among IFX initiators, there was no observed difference in clinical outcomes or drug levels, perhaps due to weight-based dosing and/or greater use of proactive drug monitoring.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns creation of a pharmaceutical composition with a wide spectrum of pharmacological activity, namely exhibiting antihypoxic, neuroprotective and antiamnestic activity, and also showing an ergogenic nature. The declared pharmaceutical composition contains semax and choline. The outcome of experiments proves that the offered pharmaceutical composition containing semax and choline, mutually intensifies an effect of each of them. ^ EFFECT: composition can find application in creation of the new drug preparations exhibiting neuroprotective activity in a combination with antihypoxic and antiamnestic activity and the ergogenic nature and used for treatment of various pathologies of the central nervous system. ^ 12 tbl, 4 dwg
It is well established that individuals differ in their response to sleep loss. However, existing methods to predict an individual's sleep-loss phenotype are not scalable or involve effort-dependent neurobehavioural tests. To overcome these limitations, we sought to predict an individual's level of resilience or vulnerability to sleep loss using electroencephalographic (EEG) features obtained from routine night sleep. To this end, we retrospectively analysed five studies in which 96 healthy young adults (41 women) completed a laboratory baseline-sleep phase followed by a sleep-loss challenge. After classifying subjects into sleep-loss phenotypic groups, we extracted two EEG features from the first sleep cycle (median duration: 1.6 h), slow-wave activity (SWA) power and SWA rise rate, from four channels during the baseline nights. Using these data, we developed two sets of logistic regression classifiers (resilient versus not-resilient and vulnerable versus not-vulnerable) to predict the probability of sleep-loss resilience or vulnerability, respectively, and evaluated model performance using test datasets not used in model development. Consistently, the most predictive features came from the left cerebral hemisphere. For the resilient versus not-resilient classifiers, we obtained an average testing performance of 0.68 for the area under the receiver operating characteristic curve, 0.72 for accuracy, 0.50 for sensitivity, 0.84 for specificity, 0.61 for positive predictive value, and 3.59 for likelihood ratio. We obtained similar performance for the vulnerable versus not-vulnerable classifiers. These results indicate that logistic regression classifiers based on SWA power and SWA rise rate from routine night sleep can largely predict an individual's sleep-loss phenotype.
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention describes new compounds of the formula (I) or their pharmaceutically acceptable salts where   means a stable 8-10-membered bicyclic heterocycle each ring of that can be saturated or unsaturated and indicated heterocycle consists of carbon atoms and 1-3 heteroatoms taken among the group including atoms N, S or O. Indicated heterocycle can be unsubstituted or substituted with halogen atom or lower C 1-4 -alkyl at condition that   is not groups (A). Compounds are inhibitors of protease of human immunodeficiency virus. Invention describes also a pharmaceutical composition based on compounds of the formula (I) and a method of inhibition of HIV-protease. EFFECT: new compounds indicated above as protease inhibitors. 14 cl, 2 dwg, 10 ex
Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone.

###  Triazolam

When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests. If triazolam is coadministered with nefazodone, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see CONTRAINDICATIONS and PRECAUTIONS).

###  Alprazolam

When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for nefazodone.
<P>PROBLEM TO BE SOLVED: To provide a system capable of selectively and efficiently processing only a part of an object to be processed at a molecular level without influencing the object to be processed by combining a tra-hertz wave with other energy supplying means.  <P>SOLUTION: In this system, when an object is irradiated by a tera-hertz wave with an intrinsic frequency of the object to be irradiated, a position to be irradiated is set to prescribed temperature by cooling/heating means. Irradiating an electromagnetic wave with a prescribed frequency, the tera-hertz wave irradiation system irradiates the object by a prescribed mode. Applying a prescribed voltage, the tera-hertz wave irradiation system irradiates an object by a prescribed mode. Applying a prescribed magnetic field, the tera-herts wave irradiation system irradiates an object by a prescribed mode. Applying a prescribed dynamic stimulation, the tera-herts wave irradiation system irradiates an object by a prescribed mode. Supplying prescribed enzymes etc., the tera-hertz wave irradiation system irradiates an object by a prescribed mode. The system uses these manners in a combination. The tera-hertz wave irradiation system uses an optimally structured metallic antenna to widen the action of a tera-hertz wave.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The recommended initial dosage of trandolapril tablets for patients not receiving a diuretic is 1 mg once daily in non-black patients and 2 mg in black patients. Dosage should be adjusted according to the blood pressure response. Generally, dosage adjustments should be made at intervals of at least 1 week. Most patients have required dosages of 2 to 4 mg once daily. There is little clinical experience with doses above 8 mg. 

Patients inadequately treated with once-daily dosing at 4 mg may be treated with twice-daily dosing. If blood pressure is not adequately controlled with trandolapril tablets monotherapy, a diuretic may be added. 

In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally can occur following the initial dose of trandolapril tablets. To reduce the likelihood of hypotension, the diuretic should, if possible, be discontinued two to three days prior to beginning therapy with trandolapril tablets. (See WARNINGS.) Then, if blood pressure is not controlled with trandolapril tablets alone, diuretic therapy should be resumed. If the diuretic cannot be discontinued, an initial dose of 0.5 mg trandolapril tablets should be used with careful medical supervision for several hours until blood pressure has stabilized. The dosage should subsequently be titrated (as described above) to the optimal response. (See WARNINGS and PRECAUTIONS, Drug Interactions.) 

Concomitant administration of trandolapril tablets with potassium supplements, potassium salt substitutes, or potassium sparing diuretics can lead to increases of serum potassium. (See PRECAUTIONS.)
1531341 Waving hair I YAMAZAKI 10 Feb 1976 [5 Sept 1975] 05209/76 Heading D1P Human hair is permanently waved by applying an aqueous reducing agent solution containing 3 to 10% by weight of a mercaptan acid or a mixture of mercaptan acids and having a pH 0.1 to 2.0 lower than the isoelectric point of the hair, allowing the thus treated hair to stand for 8 to 30 minutes whilst protected from air, then applying to the thus treated hair an aqueous oxidising agent solution containing 1 to 10% by weight of sodium bromate, potassium bromate or hydrogen peroxide and a pH 0.1 to 2.0 lower than that of the reducing solution but no more than 3.0 lower than the isoelectric point of the hair, then either refreshing the oxidising solution with additional oxidising agent and acid or applying a fresh aqueous oxidising agent solution, the fresh or refreshed oxidising agent solution having (i) an initial pH lower than the initial pH of the initial oxidising solution but not more than 3.0 below the isoelectric point of the hair, and (ii) an initial oxidising agent concentration of 1 to 5% by weight, the hair being treated with the fresh or refreshed oxidising solution for 5 to 30 minutes then washed and dried. The mercaptan acid may be thioglycolic acid and/or thiolactic acid. The reducing and oxidising solutions are preferably at 20 to 40‹C. The reduced hair may be wound on rollers before the oxidising solution is applied. The oxidising solution may be circulated, e.g. applied as a shower. The pH may be adjusted with citric, tartaric, succinic, oxalic, nitric or hydrochloric acid, ammonia, mono- or triethanolamine or an inorganic base. The reducing solution may contain 5 to 15% glycerol and the oxidising solution 0.1 to 4% glutamic acid.
OBJECTIVE: Assess cost and complication outcomes after liver transplantation (LT) using normothermic machine perfusion (NMP).
BACKGROUND: End-ischemic NMP is often used to aid logistics, yet its impact on outcomes after LT remains unclear, as does its true impact on costs associated with transplantation.
METHODS: Deceased donor liver recipients at 2 centers (January 1, 2019, to June 30, 2023) were included. Retransplants, splits, and combined grafts were excluded. End-ischemic NMP (OrganOx-Metra) was implemented in October 2022 for extended-criteria donation after brain death (DBDs), all donations after circulatory deaths (DCDs), and logistics. NMP cases were matched 1:2 with static cold storage controls (SCS) using the Balance-of-Risk [donation after brain death (DBD)-grafts] and UK-DCD Score (DCD-grafts).
RESULTS: Overall, 803 transplantations were included, 174 (21.7%) receiving NMP. Matching was achieved between 118 NMP-DBDs with 236 SCS; and 37 NMP-DCD with 74 corresponding SCS. For both graft types, median inpatient comprehensive complications index values were comparable between groups. DCD-NMP grafts experienced reduced cumulative 90-day comprehensive complications index (27.6 vs 41.9, P =0.028). NMP also reduced the need for early relaparotomy and renal replacement therapy, with subsequently less frequent major complications (Clavien-Dindo ≥IVa). This effect was more pronounced in DCD transplants. NMP had no protective effect on early biliary complications. Organ acquisition/preservation costs were higher with NMP, yet NMP-treated grafts had lower 90-day pretransplant costs in the context of shorter waiting list times. Overall costs were comparable for both cohorts.
CONCLUSIONS: This is the first risk-adjusted outcome and cost analysis comparing NMP and SCS. In addition to logistical benefits, NMP was associated with a reduction in relaparotomy and bleeding in DBD grafts, and overall complications and post-LT renal replacement for DCDs. While organ acquisition/preservation was more costly with NMP, overall 90-day health care costs-per-transplantation were comparable.
PROBLEM TO BE SOLVED: To produce an Ume(a Japanese apricot) flesh jam having high pharmacological effects and a flavor by skillfully utilizing Ganoderma kucidum Karst. and an Ume fruit containing large amounts of active ingredients for maintaining and promoting the health, enabling the extraction of the active ingredients in the Ganoderma lucidum Karst. in a state close to a natural tissue, immersing the Ume fruit in the resultant extracted essence, then facilitating the separation of a stone from the Ume flesh and immersing the essence in the Ume flesh and to provide a method for producing the Ume flesh jam. SOLUTION: This Ume flesh jam is produced by immersing a fruit body of Ganoderma lucidum Karst. in an aqueous solution containing an organic acid, saccharides and an antioxidant, carrying out the extraction by a cold temperature extracting method, preparing the first extracted essence of the Ganoderma lucidum Karst., extracting the fruit body of the Ganoderma lucidum Karst. which is a residue obtained by the extraction with an aqueous solution containing the organic acid and saccharides under heating, obtaining the second extracted essence of the Ganoderma lucidum Karst., mixing the first and second extracted essences and impregnating an Ume flesh with the resultant complex extracted essence of the Ganoderma lucidum Karst.
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib. Subjects must have a diagnosis of a myeloproliferative neoplasm and progressed or become intolerant to any JAK2 directed therapy. To be eligible for the therapy, patients are required to consent to a bone marrow biopsy at the beginning of study treatment. The treatment protocol involves initiating pacritinib on day -7 (lead-in phase, starting day -7 for cycle 1) with a standard of care dose of 200mg twice daily (BID). Subsequently, talazoparib will be given on day 1 of the treatment cycle. Cohort 1 will enroll patients at the starting dose of 0.25mg talazoparib for 14 days (dose level 1) and DLT (dose-limiting toxicity) rate will inform the subsequent dose levels (DLs).

Investigators plan to use a Bayesian Optimal Interval Design (BOIN) to determine the maximum tolerated dose (MTD) in patients with Ph-MPNs (Philadelphia chromosome negative myeloproliferative neoplasms) who have either not responded to or cannot tolerate ruxolitinib monotherapy. Subjects who are currently receiving JAK2-directed therapy will undergo a one-day washout period before starting the study treatment, as abrupt discontinuation of JAK2 inhibition can lead to side effects. This brief interval allows for the resolution of any lingering effects before initiating the new treatment. A bone marrow aspirate and or biopsy will be obtained to assess response to therapy at the end of each cycle of treatment (28 days), prior to beginning the next cycle as per physician discretion. Peripheral blood and bone marrow mononuclear cells will be checked for γ-H2AX (histone H2A family X) at set time points as a biomarker assay to assess for DNA damage in the same manner as the pre-clinical models published in our previous studies. Patients may remain on study drug unless they experience an unacceptable toxicity, fail to show a benefit, or they attain remission and it is felt by the investigator that they can proceed to an allogenic stem cell transplant.
Functional hypothalamic amenorrhea (FHA) is one of the most common causes of both primary and secondary amenorrhea in women of reproductive age. It is characterized by chronic anovulation and the absence of menses that appear as a result of stressors such as eating disorders, excessive exercise, or psychological distress. FHA is presumed to be a functional disruption in the pulsatile secretion of hypothalamic gonadotropin-releasing hormone, which in turn impairs the release of gonadotropin. Hypoestrogenism is observed due to the absence of ovarian follicle recruitment. Numerous neurotransmitters have been identified which play an important role in the regulation of the hypothalamic-pituitary-ovarian axis and of which the impairment would contribute to developing FHA. In this review we summarize the most recent advances in the identification of contributing neuroendocrine disturbances and relevant contributors to the development of FHA.